At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BCRX Biocryst Pharmaceuticals
Post-Mkt 08-07 16:02:55 EDT
9.38
+0.08
+0.86%
盘后9.38
+0.000.00%
16:01 EDT
High9.67Low9.23Vol4.38M
Open9.50D1 Closing9.30Amplitude4.68%
Mkt Cap2.40BTradable Cap2.07BTotal Shares255.54M
T/O41.14MT/O Rate1.98%Tradable Shares221.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

SIGA Technologies Q2 Revenue, Profit Drop as Contract Ends
Reuters  ·  08-07 04:15
SIGA Technologies Q2 Revenue, Profit Drop as Contract Ends
BioCryst Pharmaceuticals Price Target Cut to $20.00/Share from $21.00 by Wedbush
Dow Jones  ·  08-07 00:00
BioCryst Pharmaceuticals Price Target Cut to $20.00/Share from $21.00 by Wedbush
Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook
Reuters  ·  08-06 23:12
Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook
Zevra Therapeutics Q2 Revenue Rises 53% on Miplyffa Sales
Reuters  ·  08-06 05:10
Zevra Therapeutics Q2 Revenue Rises 53% on Miplyffa Sales
Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone
Reuters  ·  08-06 04:22
Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone
Emergent BioSolutions Swings to Q2 Loss on Impairment Charge; to Cut Jobs
Reuters  ·  08-06 04:19
Emergent BioSolutions Swings to Q2 Loss on Impairment Charge; to Cut Jobs
Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating
MT Newswires Live  ·  08-06 00:27
Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating
BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised
MT Newswires Live  ·  08-05 21:35
BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised
BioCryst Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-05 21:31
BioCryst Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
UroGen Pharma Q2 Revenue Beats on Strong Zusduri Sales
Reuters  ·  08-05 20:11
UroGen Pharma Q2 Revenue Beats on Strong Zusduri Sales
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.15
MT Newswires Live  ·  08-05 19:17
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.15
BioCryst Pharma Q2 EPS $0.30, Sales $218.250M Beat $182.514M Estimate
Benzinga Earnings  ·  08-05 19:04
BioCryst Pharma Q2 EPS $0.30, Sales $218.250M Beat $182.514M Estimate
BioCryst Pharmaceuticals Outlook FY Sales USD 690-715 Million
THOMSON REUTERS  ·  08-05 19:00
BioCryst Pharmaceuticals Outlook FY Sales USD 690-715 Million
BioCryst Pharmaceuticals Q2 EPS USD 0.3
THOMSON REUTERS  ·  08-05 19:00
BioCryst Pharmaceuticals Q2 EPS USD 0.3
BioCryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash and Investments $354 Mln at June 30, 2026
THOMSON REUTERS  ·  08-05 19:00
BioCryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash and Investments $354 Mln at June 30, 2026
BioCryst Pharmaceuticals - Expects Additional Costs for Discovery Center Closure; Analysis Ongoing - SEC Filing
THOMSON REUTERS  ·  08-04
BioCryst Pharmaceuticals - Expects Additional Costs for Discovery Center Closure; Analysis Ongoing - SEC Filing
BioCryst Pharmaceuticals - Estimates $6.2-$7.50 Mln in One-Time Expenses for Termination Benefits, $5.3-$6.60 Mln Cash - SEC Filing
THOMSON REUTERS  ·  08-04
BioCryst Pharmaceuticals - Estimates $6.2-$7.50 Mln in One-Time Expenses for Termination Benefits, $5.3-$6.60 Mln Cash - SEC Filing
BioCryst Amends 8-K, Estimates $6.2 Million-$7.5 Million in One-Time Severance Costs for Discovery Shutdown Plan
Reuters  ·  08-04
BioCryst Amends 8-K, Estimates $6.2 Million-$7.5 Million in One-Time Severance Costs for Discovery Shutdown Plan
BioCryst Pharmaceuticals (BCRX) Faces A Valuation Test, Is The Undervalued Case Convincing?
Simply Wall St.  ·  08-04
BioCryst Pharmaceuticals (BCRX) Faces A Valuation Test, Is The Undervalued Case Convincing?
Earning Preview: Biocryst Pharmaceuticals Q2 revenue is expected to increase by 21.89%, and institutional views are cautiously optimistic
Earnings Agent  ·  07-29
Earning Preview: Biocryst Pharmaceuticals Q2 revenue is expected to increase by 21.89%, and institutional views are cautiously optimistic

Introduction

Company Name.
Biocryst Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Issue price:
--